Filing summary
Entity discrepancy: The request identifies Viridian Therapeutics, Inc., but the supplied Form 10-Q is for Signal Genetics, Inc. The summary below reflects the filing provided, not Viridian Therapeutics.
Business context and reporting period
Signal Genetics was a commercial-stage molecular diagnostics company focused on cancer testing. Its primary product was MyPRS, a gene-expression test for multiple myeloma. This unaudited Form 10-Q covers the quarter and six months ended June 30, 2015, compared with the corresponding 2014 periods. The company reported one operating segment and U.S.-only operations.
Financial performance and position
Amounts below are in millions of dollars except per-share data and percentages.
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Net revenue | $0.734 | $1.274 | $1.378 | $2.364 |
| Gross profit (loss) | $0.056 | $0.320 | ($0.061) | $0.679 |
| Gross margin | 7.6% | 25.1% | (4.4%) | 28.7% |
| Operating loss | ($2.490) | ($2.811) | ($5.102) | ($2.978) |
| Net loss | ($2.562) | ($3.289) | ($5.196) | ($3.995) |
| Basic and diluted loss per share | ($0.33) | ($4.73) | ($0.77) | ($8.92) |
Six-month operating cash use was $3.295 million, versus $0.385 million in 2014. Investing cash use was $0.068 million. Financing provided $8.692 million, principally from the February 2015 stock offering. Cash rose to $10.448 million at June 30, 2015, from $5.119 million at year-end 2014. Working capital was $9.8 million. Current liabilities were $2.075 million; total liabilities were approximately $2.151 million. These included a $1.105 million related-party note payable on demand, bearing 8% interest, and a $0.128 million capital lease obligation.
Material changes versus prior periods
- Revenue declined 42% in both Q2 and the first half. The filing attributes much of the reduction to lower UAMS research-program activity and reduced estimates of collections from non-contracted payors.
- Tests billed to non-UAMS hospitals and direct-billed customers increased 63% in Q2 and 46% in the first half, but this growth did not offset declines in UAMS-related activity and lower recognized revenue.
- Contractual allowances rose to 50% of gross revenue in the first half, from 24% in the comparable 2014 period. The company recorded unfavorable prior-year revenue estimate adjustments of $43,000 in Q2 and $73,000 in the first half.
- Cost of revenue fell, but less quickly than revenue; it equaled 92% of Q2 revenue and 104% of first-half revenue. Selling and marketing expense rose substantially as the company expanded its sales and managed-care functions. First-half R&D expense also increased.
- First-half net loss increased, although Q2 net loss was lower than the comparative period. Lower interest expense and lower Q2 stock-based compensation contributed to the Q2 comparison.
- The February 2015 offering and overallotment issued approximately 3.70 million shares and generated $9.074 million net financing proceeds, before related noncash offering compensation accounting. Shares outstanding increased to 7,845,530 at June 30, 2015 from 3,782,629 at December 31, 2014.
Outlook, commentary, and risks
- Management expected continued losses and negative operating cash flow while funding sales, marketing, and R&D, but stated cash on hand was sufficient to support operations for at least one year from the report date. It cautioned that future financing or strategic investment might be needed and was not assured; absent funding, spending or plans could need to be reduced.
- Management expected continued declines in UAMS research-program revenue, while planning further sales-force and marketing expansion and additional diagnostic development. No quantified revenue, earnings, or cash-flow guidance was provided.
- A June 2015 master services agreement with a pharmaceutical company covered MyPRS testing across multiple clinical trials; the first of four studies had been initiated. An August 2015 agreement with America’s Choice Provider Network was expected by management to improve reimbursement support over the long term.
- Customer concentration was significant: UAMS-sourced revenue represented 72% of Q2 revenue and 75% of first-half revenue. UAMS accounted for 55% of receivables at quarter-end. Inventory depended on one supplier.
- Revenue estimates for non-contracted payors were uncertain. The filing noted $210,000 of uncollected non-contracted receivables and estimated that a comparable 26.9% collection reduction could cause an additional $57,000 unfavorable impact.
- The company reported no current legal proceedings and no material changes to the risk factors in its 2014 Form 10-K. Disclosure controls were considered effective at a reasonable-assurance level; management had not yet completed an assessment of internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is Signal Genetics, Inc., not Viridian Therapeutics, Inc.
- Review the sustainability and collectability of revenue, particularly non-contracted payor estimates, contractual allowances, and the large aged receivable balance.
- Track UAMS research-program funding and customer concentration, alongside growth in non-UAMS hospital and direct-billed activity.
- Assess cash runway against the reported operating cash burn, planned commercial and R&D spending, and the availability and potential dilution of additional financing, including the $4.45 million ATM program authorized after quarter-end.
- Monitor the related-party demand note, future reimbursement coverage, and whether the pharmaceutical clinical-trial agreement and ACPN relationship produce measurable revenue or collections.